Loading stock…

Thermo Fisher Scientific Inc. (TMO) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Thermo Fisher Scientific Inc.

TMOMarket cap $241BPrice $652.0

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Thermo Fisher Scientific makes lab equipment and consumables used in virtually every major drug discovery and medical breakthrough. Their tools helped develop COVID vaccines and analyze samples in over 400,000 laboratories worldwide.

In Bastion Portfolios?

52W Return+21%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-0%3

Revenue Forecast

Rev CAGR (1y)+7%5

Rev CAGR (3y)+6%5

Rev CAGR (5y)+6%5

Earnings Forecast

EPS Growth Y+1+42%9

EPS Growth Y+2+8%6

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin19%7

Net Income Margin15%7

Free Cash Flow Margin16%7

Debt

Net Debt/EBITDA3.13

Efficiency

ROE14%6

ROA7%7

Earnings Stability55

GEAR+AVERAGE48

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)253

P/E Ratio (Forward 3y)222

P/BV4.63

EV Multiples

EV/EBITDA Fwd222

EV/EBIT Fwd253

Yield

Free Cash Flow Yield3.0%5

Dividend Yield0.3%1

Momentum

Short term

1 month return+8%10

3 month return+24%10

YTD return+13%7

Mid term

Price vs 52wHigh94%9

1 year return+22%7

Long term

3 year return+33%5

5 year return+13%4

Risk Shield

Price Risk

Beta0.76

Volatility29%7

Free Cash Flow

Free Cash Flow Margin16%7

Free Cash Flow Yield3.0%5

Quality

ROCE9%5

Earnings Stability55

Net Debt/EBITDA3.13

02Growth

Is it actually growing, and how fast?

TMOThermo Fisher Scientific

Revenue FY25$44.6B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+42%9

EPS growth, FY27E+8%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 6%/yr from here.

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, in line with the market.5/10

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG84 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+8%10

3-month return+24%10

YTD return+13%7

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+22%7

3-year return+33%5

5-year return+13%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 22% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+8%), over three months (+24%) and so far this year (+13%).

WATCH

Average long-term results. Multi-year returns are middling (+33% over three years and +13% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Thermo Fisher. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TMOThermo Fisher Scientific

Revenue FY25$44.6B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-0%3

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+42%9

EPS growth, FY27E+8%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to grow 6%/yr from here.

Earnings are set to grow in step with sales (EPS about 9%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, in line with the market.5/10

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

WEAKNESSES

Revenue held flat over the last 3 years, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG84 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+8%10

3-month return+24%10

YTD return+13%7

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+22%7

3-year return+33%5

5-year return+13%4

MOMENTUM ASSESSMENT

STRENGTHS

It's up 22% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+8%), over three months (+24%) and so far this year (+13%).

WATCH

Average long-term results. Multi-year returns are middling (+33% over three years and +13% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Thermo Fisher. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community